Search Within

Serge K. Lyashchenko

Formats
  1. Journal Article (55)
  2. Meeting Abstract (45)
  3. Review (4)
  4. Book Section (3)
  5. Correspondence (1)
Groups
  1. Radiochemistry and Imaging Sciences Service (108)
  2. Radiology, Department of (108)
  3. GSK Faculty (97)
  4. Molecular Imaging and Therapy Service (89)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (82)
  6. Center for Pancreatic Cancer Research (81)

More Groups

People
  1. Jason Lewis (75)
  2. Neeta Pandit-Taskar (52)
  3. Steven Larson (46)
  4. Jorge Carrasquillo (36)
  5. Joseph O'Donoghue (33)
  6. Pat Zanzonico (32)

More People

Years
  1. 2025 (2)
  2. 2024 (14)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (2)
  6. 2020 (11)

More Years

Publications
  1. Journal of Nuclear Medicine (28)
  2. Journal of Clinical Oncology (17)
  3. European Journal of Nuclear Medicine and Molecular Imaging (6)
  4. Neuro-Oncology (6)
  5. Clinical Cancer Research (5)
  6. Pediatric Blood and Cancer (5)

More Publications

Publishers
  1. Society of Nuclear Medicine (28)
  2. American Society of Clinical Oncology (17)
  3. Springer (11)
  4. Oxford University Press (9)
  5. American Association for Cancer Research (7)
  6. Wiley Periodicals, Inc (5)

More Publishers

Results (108)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer
    Meeting Abstract

    Backhaus, P.; Pentlow, K.; Ho, A. L.; Mauguen, A.; Fagin, J. A.; Pillarsetty, N. V. K.; Lyashchenko, S. K.; Burnazi, E.; Ghossein, R. A.; Chhabra, S.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • Detection of HER2-low lesions using HER2-targeted PET imaging in patients with HER2-negative metastatic breast cancer
    Meeting Abstract

    Yeh, R.; Lyashchenko, S. K.; Zeglis, B. M.; Lewis, J. S.; Ulaner, G. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2023)

    Fulltext@MSK | Save
  • (18)F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG
    Meeting Abstract

    Modak, S.; Mauguen, A.; Basu, E. M.; Price, A.; Behr, G.; Min, R.; Lyashchenko, S. K.; Schwartz, J.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study
    Journal Article

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Radiopharmaceutical legislation
    Book Section

    Decristoforo, C.; Lyashchenko, S. K.
    In Signore, A. (Eds.) Nuclear Medicine and Molecular Imaging (2022)

    Fulltext@MSK | Save
  • Performance of clinical trials with radiopharmaceuticals in the United States
    Book Section

    Lyashchenko, S. K.; Vietri, S. M.; Park, H. A.; Kourlas, G.
    In Signore, A. (Eds.) Nuclear Medicine and Molecular Imaging (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Meeting Abstract

    Modak, S.; Pandit Taskar, N.; Kushner, B.; Zanzonico, P.; Humm, J.; Donzelli, M.; Lewis, J.; Lyashchenko, S.; Chu, B.; Larson, S.; more...
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Journal Article

    Kramer, K.; Pandit-Taskar, N.; Kushner, B. H.; Zanzonico, P.; Humm, J. L.; Tomlinson, U.; Donzelli, M.; Wolden, S. L.; Haque, S.; Dunkel, I.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save